Business Wire

ADVA announces preliminary results for fiscal year 2022

21.2.2023 07:00:00 EET | Business Wire | Press release

Share

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported preliminary, unaudited financial results for Q4 2022 and full year 2022 ended on December 31, 2022. The results have been prepared in accordance with International Financial Reporting Standards (IFRS). The final audited annual financial statements, consolidated financial statements and annual report 2022 will be published on March 09, 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005296/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Christoph Glingener, CEO, ADVA (Photo: Business Wire)

Q4 2022 financial summary1

(in thousands of EUR)

Q4

Q4

Change

Q3

Change

 

2022

2021

 

2022

 

 

Revenues

195,699

157,713

24.1%

179,597

9.0%

Pro forma gross profit

71,434

56,072

27.4%

60,857

17.4%

in % of revenues

36.5%

35.6%

0.9pp

33.9%

2.6pp

Pro forma EBIT

24,407

14,362

69.9%

11,732

108.0%

in % of revenues

12.5%

9.1%

3.4pp

6.5%

6.0pp

Operating income2

14,803

11,190

32.3%

-7,322

n/a

Net income

3,781

17,511

-78.4%

881

329 .2%

 

(in thousands of EUR)

Dec. 31

2022

Dec. 31

2021

Change

Sep. 30

2022

Change

Cash and cash equivalents

58,447

108,987

-46.4%

61,381

-4.8%

Net cash (+) / Net debt (-)

-19,185

36,166

n/a

-17,434

10.0%

1 Potential difference due to rounding

2 Q4 2022 including EUR 3.3 million, Q4 2021 including EUR 1.6 million and Q3 2022 including EUR 17.1 million extraordinary expenses

Q4 2022 IFRS financial results

Revenues in Q4 2022 reached EUR 195.7 million, up by 9.0% from EUR 179.6 million in Q3 2022, also up by 24.1% compared to EUR 157.7 million in Q4 2021. This was due, in particular, to very high demand from telecommunications service providers.

Pro forma gross profit in Q4 2022 increased by 17.4%, reaching EUR 71.4 million (36.5% of revenues) compared to EUR 60.9 million (33.9% of revenues) in Q3 2022 and increased by 27.4% compared to EUR 56.1 million (35.6% of revenues) reported in Q4 2021. The margin increase was due to a reduction in freight costs and expedited fees associated with the semiconductor crisis.

Pro forma EBIT for Q4 2022 was EUR 24.4 million (12.5% of revenues) and increased by 108.0% compared to EUR 11.7 million (6.5% of revenues) reported in Q3 2022. Compared to Q4 2021, pro forma EBIT improved by 69.9% from EUR 14.4 million (9.1% of revenues).

Operating income for Q4 2022 of EUR 14.8 million increased from an operating loss of EUR 7.3 million reported for Q3 2022 and increased by 32.3% from EUR 11.2 million in Q4 2021. The year-ago quarter was impacted by higher purchasing costs, and the previous quarter was impacted by both higher purchasing costs and expenses related to the business combination with Adtran.

Net income reached EUR 3.8 million in Q4 2022 and increased by 329.2% from EUR 0.9 million in Q3 2022 but decreased by 78.4% from EUR 17.5 million in Q4 2021.

The company’s cash and cash equivalents totaled EUR 58.4 million, compared to EUR 61.4 million at the end of Q3 2022 or EUR 109.0 million at the end of Q4 2021. Net debt at the end of Q4 2022 stood at EUR 19.2 million compared to EUR 17.4 million at the end of Q3 2022 or a net cash position of EUR 36.2 million at the end of Q4 2021. The comparatively high level of net debt is attributable to higher debt-financed inventories.

Full year 2022 financial summary1

(in thousands of EUR)

2022

2021

Change

Revenues

712,114

603,317

18.0%

Pro forma gross profit

240,032

220,844

8.7%

in % of revenues

33.7%

36.6%

-2.9pp

Pro forma EBIT2

50,386

54,649

-7.8%

in % of revenues

7 .1%

9.1 %

-2.0pp

Operating income3

18,112

45,295

-60.0%

Net income

18,132

59,218

-69.4%

 

(in thousands of EUR)

Dec. 31 2022

Dec. 31 2021

Change

Cash and cash equivalents

58,447

108,987

-46.4%

Net cash (+) / Net debt (-)

-19,185

36,166

n/a

1 Potential differences due to rounding

2 Prior: Pro forma operating income

3 2022 including EUR 21.3 million and 2021 including EUR 3.7 million extraordinary expenses

Full year 2022 IFRS financial results

For the full year 2022, revenues increased by 18.0%, from EUR 603.3 million in 2021 to EUR 712.1 million. Revenues were within the guidance corridor of between EUR 680 million and 730 million. Despite the continuing challenges posed by global supply bottlenecks and material shortages in the semiconductor industry, ADVA substantially increased its revenues. Demand notably increased in the telecommunications service provider segment.

Pro forma gross profit increased 8.7% from EUR 220.8 million (36.6%) in 2021 to EUR 240.0 million (33.7%) in 2022. Full year gross margins were impacted by increased freight costs and expedited fees associated with the semiconductor crisis.

Pro forma EBIT for 2022 decreased by 7.8%, from 54.6 million or 9.1% of revenues in 2021 to EUR 50.4 million or 7.1% of revenues. Pro forma EBIT was within the guidance corridor of between 5.0% and 9.0%.

Operating income decreased by 60.0%, from EUR 45.3 million in 2021 to EUR 18.1 million in 2022. The results for 2022 were impacted by higher costs resulting from the supply chain crisis and expenses related to the business combination with Adtran.

Consequently, net income decreased from EUR 59.2 million in 2021 by 69.4% to EUR 18.1 million in 2022.

Basic earnings per share in 2022 amounted to EUR 0.35 compared to EUR 1.17 in 2021. Diluted earnings per share in 2022 also amounted to EUR 0.35 compared to diluted earnings per share of EUR 1.15 in 2021.

Management commentary

“We’re proud to report a highly successful fiscal year, where we achieved the highest revenues in our company’s history. Despite ongoing challenges caused by the semiconductor crisis, bottlenecks in the supply chains, inflation and fears of recession, we were able to stay on course, comprehensively serving and supporting our customers with innovative communications technology, software and services,” said Christoph Glingener, CEO of ADVA. “Looking forward, we are optimistic about future growth prospects. We have a strong pipeline of new products and services and are well-positioned to benefit from the major trends in our industry. Our capabilities in software and services are strengthening, delivering increasing value to our customers and partners. Together with Adtran, we will continue to focus on cost management and operational efficiency while investing in key areas to enter new growth markets.”

“Today, we report financial results of a strong 2022 with revenue growth of 18% year-over-year. Considering the various macroeconomic challenges and ongoing constraints in global supply chains, we’re very pleased with our profitability, which came in as expected,” commented Uli Dopfer, CFO of ADVA. “We’re optimistic that global supply chains will ease during this year and that cash generation will improve. We also expect to benefit from our business combination with Adtran and see first revenue synergies in 2023. We remain committed to increasing software and service revenues, which will drive continued margins improvement.”

The company will publish its financial results for Q1 2023 on May 09, 2023.

Conference call details

ADVA will hold a conference call for analysts and investors today, February 21, 2023, to discuss the preliminary Q4 2022 and full year 2022 results. The company’s CEO, Christoph Glingener, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CET (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website: https://www.adva.com/en/about-us/investors/financial-results/conference-calls

A replay of the call will be available here: https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete annual report 2022 (January – December) will be published on March 09, 2023.

Forward-looking statements

The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information

ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, non-recurring expenses related to M&A and restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Steven Williams
t +49 89 890 66 59 18
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye